161 related articles for article (PubMed ID: 38252195)
21. Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma.
Kirino S; Tsuchiya K; Kurosaki M; Kaneko S; Inada K; Yamashita K; Osawa L; Hayakawa Y; Sekiguchi S; Okada M; Wang W; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Izumi N
PLoS One; 2020; 15(4):e0231828. PubMed ID: 32310967
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic efficacy of lenvatinib for patients with unresectable hepatocellular carcinoma based on the middle-term outcome.
Fuchigami A; Imai Y; Uchida Y; Uchiya H; Fujii Y; Nakazawa M; Ando S; Sugawara K; Nakayama N; Tomiya T; Mochida S
PLoS One; 2020; 15(4):e0231427. PubMed ID: 32275701
[TBL] [Abstract][Full Text] [Related]
23. Association between treatment-emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in the REFLECT study.
Piscaglia F; Ikeda K; Cheng AL; Kudo M; Ikeda M; Breder V; Ryoo BY; Mody K; Ren M; Ramji Z; Sung MW
Cancer; 2024 Apr; 130(8):1281-1291. PubMed ID: 38261521
[TBL] [Abstract][Full Text] [Related]
24. Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma.
Hiraoka A; Kumada T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Imai M; Joko K; Koizumi Y; Hiasa Y; Michitaka K;
Oncology; 2019; 97(6):334-340. PubMed ID: 31466068
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib: A retrospective analysis.
Dong D; Shi JY; Shang X; Liu B; Xu WL; Cui GZ; Wang NY
Medicine (Baltimore); 2022 Feb; 101(5):e28680. PubMed ID: 35119010
[TBL] [Abstract][Full Text] [Related]
26. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study.
Fu Z; Li X; Zhong J; Chen X; Cao K; Ding N; Liu L; Zhang X; Zhai J; Qu Z
Hepatol Int; 2021 Jun; 15(3):663-675. PubMed ID: 33877527
[TBL] [Abstract][Full Text] [Related]
27. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Kudo M; Finn RS; Qin S; Han KH; Ikeda K; Piscaglia F; Baron A; Park JW; Han G; Jassem J; Blanc JF; Vogel A; Komov D; Evans TRJ; Lopez C; Dutcus C; Guo M; Saito K; Kraljevic S; Tamai T; Ren M; Cheng AL
Lancet; 2018 Mar; 391(10126):1163-1173. PubMed ID: 29433850
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of Lenvatinib Versus Sorafenib for Unresectable Hepatocellular Carcinoma in Patients with Hepatic Decompensation.
Park MK; Lee YB; Moon H; Choi NR; Kim MA; Jang H; Nam JY; Cho EJ; Lee JH; Yu SJ; Kim YJ; Yoon JH
Dig Dis Sci; 2022 Oct; 67(10):4939-4949. PubMed ID: 35048224
[TBL] [Abstract][Full Text] [Related]
29. ALBI Grade Is a Predictive Factor of Lenvatinib Treatment Discontinuation due to Adverse Events in Hepatocellular Carcinoma.
Enomoto D; Yamamoto K; Matsumoto Y; Morioka A; Omura T; Komatsu S; Yano Y; Fukumoto T; Yano I
Anticancer Res; 2023 Mar; 43(3):1317-1323. PubMed ID: 36854508
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness and safety of lenvatinib plus anti-programmed death-1 antibodies in patients with hepatocellular carcinoma: A real-world cohort study.
Xu MH; Huang C; Li ML; Zhu XD; Tan CJ; Zhou J; Fan J; Sun HC; Shen YH
Cancer Med; 2023 Apr; 12(8):9202-9212. PubMed ID: 36790032
[TBL] [Abstract][Full Text] [Related]
31. Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA.
Singal AG; Nagar SP; Hitchens A; Davis KL; Iyer S
Future Oncol; 2021 Jul; 17(21):2759-2768. PubMed ID: 33832339
[TBL] [Abstract][Full Text] [Related]
32. The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study.
Tsuchiya K; Kurosaki M; Sakamoto A; Marusawa H; Kojima Y; Hasebe C; Arai H; Joko K; Kondo M; Tsuji K; Sohda T; Kimura H; Ogawa C; Uchida Y; Wada S; Kobashi H; Furuta K; Shigeno M; Kusakabe A; Akahane T; Narita R; Yoshida H; Mitsuda A; Ide Y; Matsushita T; Izumi N; On Behalf Of Japanese Red Cross Liver Study Group
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34073396
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma.
Ando Y; Kawaoka T; Amioka K; Naruto K; Ogawa Y; Yoshikawa Y; Kikukawa C; Kosaka Y; Uchikawa S; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Takahashi S; Imamura M; Chayama K; Aikata H
Oncology; 2021; 99(8):507-517. PubMed ID: 33946070
[TBL] [Abstract][Full Text] [Related]
34. REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset.
Yamashita T; Kudo M; Ikeda K; Izumi N; Tateishi R; Ikeda M; Aikata H; Kawaguchi Y; Wada Y; Numata K; Inaba Y; Kuromatsu R; Kobayashi M; Okusaka T; Tamai T; Kitamura C; Saito K; Haruna K; Okita K; Kumada H
J Gastroenterol; 2020 Jan; 55(1):113-122. PubMed ID: 31720835
[TBL] [Abstract][Full Text] [Related]
35. Liver Function in Older Patients With Unresectable Hepatocellular Carcinoma After Administration of Lenvatinib.
Sasaki R; Fukushima M; Haraguchi M; Miuma S; Miyaaki H; Hidaka M; Eguchi S; Matsuo S; Matsuzaki T; Hashimoto S; Ohba K; Kugiyama Y; Yatsuhashi H; Shibata H; Motoyoshi Y; Shigeno M; Iwatsu S; Kato Y; Kinoshita N; Nakao K
Anticancer Res; 2021 Apr; 41(4):2025-2032. PubMed ID: 33813409
[TBL] [Abstract][Full Text] [Related]
36. Neutrophil-to-lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib.
Tada T; Kumada T; Hiraoka A; Michitaka K; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Nakamura S; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y
Liver Int; 2020 Apr; 40(4):968-976. PubMed ID: 32064740
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab.
Kikugawa C; Uchikawa S; Kawaoka T; Kinami T; Yano S; Amioka K; Naruto K; Ando Y; Yamaoka K; Tsuge M; Kosaka Y; Ohya K; Mori N; Takaki S; Tsuji K; Kouno H; Kohno H; Morio K; Moriya T; Nonaka M; Aisaka Y; Masaki K; Honda Y; Naeshiro N; Hiramatsu A; Aikata H; Oka S
Oncology; 2024; 102(3):239-251. PubMed ID: 37729889
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China.
Wang DX; Yang X; Lin JZ; Bai Y; Long JY; Yang XB; Seery S; Zhao HT
World J Gastroenterol; 2020 Aug; 26(30):4465-4478. PubMed ID: 32874058
[TBL] [Abstract][Full Text] [Related]
39. Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study.
Chen S; Xu B; Wu Z; Wang P; Yu W; Liu Z; Huang X; Wu Y; Li T; Guo W
BMC Cancer; 2021 Oct; 21(1):1126. PubMed ID: 34670506
[TBL] [Abstract][Full Text] [Related]
40. Lenvatinib: A Review in Hepatocellular Carcinoma.
Al-Salama ZT; Syed YY; Scott LJ
Drugs; 2019 Apr; 79(6):665-674. PubMed ID: 30993651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
